<DOC>
	<DOCNO>NCT00324649</DOCNO>
	<brief_summary>This study evaluate change body fat distribution human immunodeficiency virus type 1 ( HIV-1 ) infect participant either switch zidovudine- plus lamivudine- containing highly active antiretroviral therapy ( HAART ) regimen regimen contain TruvadaÂ® ( fixed-dose combination tablet emtricitabine [ FTC , 200 mg ] tenofovir disoproxil fumarate [ TDF , 300 mg ] ) remain zidovudine- plus lamivudine-containing regimen . Subjects continue protease inhibitor ( PI ) nonnucleoside reverse transcriptase inhibitor ( NNRTI ) .</brief_summary>
	<brief_title>Peripheral Body Fat Distribution After Switching Zidovudine Lamivudine Truvada</brief_title>
	<detailed_description>Standard care treatment HIV infection involve use combination three antiretroviral drug . The initial recommended regimen antiretroviral-naive patient accord therapeutic guideline US Department Health Human Resources ( DHHS ) include two nucleoside reverse transcriptase inhibitor ( NRTIs ) third drug another class ( PI NRTI ) . The use nucleoside analogue , especially stavudine zidovudine , associate untoward side effect , include lipodystrophy hepatic steatosis/lactic acidosis syndrome , peripheral neuropathy , anemia . However , Truvada low potential mitochondrial toxicity fat distribution disturbance . As described Consensus Document Spanish Group Study AIDS ( GESIDA ) , AIDS National Plan Spanish Ministry Health `` Recommendations metabolic alteration body fat distribution '' , study focus evaluation body fat disturbance antiretroviral drug substitution , base basic assumption virologic control patient equivalence potency new drug regard virological control . In addition , study base selective substitution antiretroviral drug HIV-1 infect patient virological control , recommend European Medicines Agency ( EMA ) `` Guideline clinical development medicinal product treatment HIV infection '' . In study , stable , virologically control , HIV-1 infect participant receive antiretroviral regimen contain zidovudine lamivudine randomize switch Truvada stay zidovudine- plus lamivudine-containing regimen . Participants group continue third drug antiretroviral regimen ( either NNRTI PI ) . Changes limb fat two group assess use dual-energy x-ray absorptiometry ( DEXA ) .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV1 infection document confirmed positive HIV1 antibody test and/or positive polymerase chain reaction HIV1 ribonucleic acid ( RNA ) . Adult patient ( 18 year age ) . Current HAART regimen contain zidovudine + lamivudine usual dose least 6 month . Viral load &lt; 50 copies/mL last two consecutive determination , zidovudine + lamivudine contain HAART regimen . For woman childbearing potential , negative urine pregnancy test screen visit . Agreement take part study sign inform consent . Patients lipid lower treatment allow participate study lipidlowering treatment ( either statins fibrates ) stable least 8 week prior screen expect change first 3 month study . Patients current FTC TDF therapy . Patients previous history virological failure FTC TDFcontaining regimen . Patients receive nonregistered antiretroviral drug . Patients receive triplenucleoside antiretroviral combination . Hypersensitivity one component dosage form TDF FTC , previous history intolerance one drug . Known history drug abuse chronic alcohol consumption Women pregnant breast feeding , female childbearing potential use adequate method contraception accord investigator 's judgment . Active opportunistic infection document infection within previous 4 week . Documented active malignant disease ( exclude Kaposi sarcoma limit skin ) . Renal disease creatinine clearance &lt; 50 mL/min . Concomitant use nephrotoxic immunosuppressive drug could stop without affect safety patient . Receiving ongoing therapy systemic corticosteroid , Interleukin2 chemotherapy . Patients include study accord investigator 's criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HIV-1</keyword>
</DOC>